Continuity plan at ANS Biotech
07 Apr 2020Working from home or on site, all the pieces of the ANS Biotech puzzle stay strongly united and mobilized to pursue to proudly serve you.
NEW OXP model now available
30 Mar 2020We all need good news... Because good news is welcome, both in good times and bad, we are pleased to announce the launch of a new version of our model of Oxaliplatin-induced cold allodynia.
COVID-19
19 Mar 2020In the current global health context, ANS Biotech is mobilizing and adapting so as not to stop its support in the services for its Customers. We remain available online and fully mobilized for your projects.
ANS Biotech on the Science Exchange platform
01 Mar 2020We are pleased to announce that ANS Biotech is now an official registered vendor on the Science Exchange platform! Visit our Provider profile (https://www.scienceexchange.com/labs/ans-biotech) and easily start a collaboration with us!
Welcome to the SNI model
10 Feb 2020The arrival of the SNI model strengthens the already available offer of services in the field of traumatic neuropathic pain.
ANSbiosamples : New service with Oroxcell
05 Apr 2019ANS Biotech announces a collaborative agreement with Oroxcell for the bioanalyses of sampled fluids & tissues !
Experience the largest biotechnology event in the world
27 Mar 2019ANS Biotech will attend 2019 BIO International Convention, Philadelphia, PA, USA. Join us in Philadelphia, PA, June 3-6, 2019 as more than 16,000 attendees.
ANS Biotech explores pain
06 Dec 2018On Tuesday the 4th of December 2018, the local newspaper “La Montagne”, had an interview with the CEO, François Caussade. READ THE ARTICLE
17 th World Congress on Pain in Boston, MA (September 12-16, 2018)
16 Sep 2018ANS Biotech attended 17th World Congress on Pain in Boston, MA (September 12-16, 2018). ANS Biotech presented a poster titled: Comparison of the antinociceptive and antipruritic effects of kappa opioid receptor agonists on models of itch and pain.